CClinicalTrials.gg
CompletedNCT06673719Updated Nov 5, 2024

Comparing Pertechnetate SPECT/CT and Intragastric Pressure During Nutrient Drink for Gastric Accommodation

An interventional study of 99mTc-pertechnetate SPECT/CT and Combined High-Resolution Manometry-Nutrient Drink Test in Healthy Volunteers and Functional Dyspepsia, sponsored by Universiti Sains Malaysia. Completed at 1 site in Malaysia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Universiti Sains Malaysia · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Oct 2019, registered Oct 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Functional dyspepsia (FD) is a common gastrointestinal disorder which can present with early satiety, postprandial fullness, epigastric pain and burning sensation in the absence of underlying disease. The most troubling symptom is weight loss, prevalent in up to 40% of FD patients and is often associated with impaired gastric accommodation.

Gastric accommodation by definition is a reflex, mediated vagally which causes reduction in gastric tone, increased in compliance and increment in gastric volume post meal ingestion. It allows large volumes of liquid or solid ingestion without causing postprandial symptoms. Impairment of gastric accommodation has been linked to gastrointestinal symptoms which includes nausea, bloating, early satiety, weight loss and epigastric pain.

There are several studies aimed to assess efficacy in the treatment of functional dyspeptic patients. A myriad of tests can measure gastric accommodation such as gastric barostat and single photon emission computed tomography (SPECT). An alternative study known as the nutrient drink test has also been proposed and can be combined with high-resolution manometry.

So far, none of the nuclear medicine centers in Malaysia are providing clinical service for radionuclide gastric accommodation study. The gold standard for gastric accommodation assessment is the gastric barostat method. However, the technique is invasive and caused discomfort to patients. Radionuclide gastric accommodation study using 99mTc-pertechnetate with SPECT/CT is a non-invasive method that can be used to assess patient with FD and enables quantitative evaluation of treatment response to medications. Hence, the role of non-invasive gastric volume assessment with 99mTc-pertechenate SPECT/CT in the evaluation of healthy individuals was studied first, and then compared with intragastric pressure measurements from high-resolution manometry and nutrient drink test.

02

Conditions studied

  • Healthy Volunteers
  • Functional Dyspepsia

Browse trials for

03

In context

Dyspepsia

363 studies on the registry are indexed under Dyspepsia; 51 are open to participants now.

This study's enrollment of 20 is below the median of 87 across 297 interventional studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Universiti Sains Malaysia is the lead sponsor of 171 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Healthy volunteers

Inclusion criteria

Inclusion Criteria:

  • Patient is above 18 years-old.
  • No current gastrointestinal symptoms
  • No previous gastrointestinal illness such as peptic ulcer disease or gastritis
  • No chronic medical illness such as chronic neurological, cardiovascular, pulmonary, endocrine and hematological disorders
  • Does not fulfill Rome IV criteria for functional dyspepsia

Exclusion criteria

Exclusion Criteria:

    • Had undergone any abdominal surgery except appendicectomy, tubal ligation or Caesarean section

      • Use of medications such as metoclopramide, domperidone, erythromycin and itopride that may alter gastrointestinal function and motility
      • Pregnant woman
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    SPECT/CT or HRM-NDT

    Radiation: 99mTc-pertechnetate SPECT/CT · Procedure: Combined High-Resolution Manometry-Nutrient Drink Test

Interventions

  • Radiation99mTc-pertechnetate SPECT/CT

    This procedure is similar to standard Meckel's diverticulum scan, with the addition of SPECT/CT acquisition to measure gastric volume.

  • ProcedureCombined High-Resolution Manometry-Nutrient Drink Test

    Proximal gastric high-resolution manometry was done concurrently with nutrient drink test to measure proximal gastric function.

06

What researchers measure

Primary outcomes

  1. Number of participants completing each procedure

    • Feasibility assessed as technical success (number of participants completing each procedure).

    Time frame: From the initiation of the first study procedure until the completion of the second procedures (up to 30 days)

  2. Duration (time) of each procedural session

    • Feasibility assessed as procedural duration (time taken to complete one procedure)

    Time frame: From the initiation of the first study procedure until the completion of the second procedures (up to 30 days)

  3. Incidence of adverse event

    • Tolerability assessed as incidence of adverse event over study period using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From the initiation of the first study procedure until the completion of the second procedures (up to 30 days)

Secondary outcomes

  1. Gastric volume measured using SPECT/CT

    • Gastric volume (in mL): Fasting state, postprandial state (after single-serving of 250 mL nutrient drink). All are to be measured in one session and as one outcome.

    Time frame: During the procedure, 1 day

  2. Proximal gastric pressure measured using high-resolution manometry

    • Proximal gastric pressure (in mmHg): baseline (fasting) pressure recording, prandial pressure recording, postprandial pressure recording. All are to be measured in one session and as one outcome.

    Time frame: During the procedure, 1 day

  3. Nutrient drink tolerance

    • Maximum tolerated volume (in mL): Number of drink volume required to achieve satiety

    Time frame: During the procedure, 1 day

  4. Dyspeptic symptoms measured using numerical rating scales

    • Dyspeptic symptom responses: Numerical rating scale with verbal descriptors on 4 symptoms i.e., epigastric pain, bloating, fullness, nausea (from 0 to 3: 0 means "no symptoms", 3 means "severe"). All are to be measured in one session using one instrument and as one outcome.

    Time frame: During the procedure, 1 day

  5. Satiation score measured using numerical rating scales

    • Satiation (presented as satiation-unit): Numerical rating scale with verbal descriptors (from 0 to 5: 0 means "not full", 5 means "maximum fullness")

    Time frame: During the procedure, 1 day

07

Study locations

1 site
  • Universiti Sains Malaysia
    Kota Bharu, Kelantan 16150, Malaysia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06673719
Lead sponsor
Universiti Sains Malaysia
Responsible party
Nashrulhaq Tagiling, MSc (Principal Investigator, Universiti Sains Malaysia) — Principal investigator
First posted
Nov 5, 2024
Start date
Oct 1, 2019
Primary completion
Feb 27, 2020
Completion
Mar 15, 2020
Last update
Nov 5, 2024

Study contacts

Yeong Yeh Lee, MD, PhD
study director · Universiti Sains Malaysia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion